Therefore, future studies should focus on the biological differences of IL-12 and IL-23 in order to determine why IL-12 can exacerbate GVHD in some contexts yet suppress it in others, yet pharmacologically targeting p40 can be efficacious in reducing GVHD severity in experimental and clinical settings. This evidence concerns the gene IL37 and graft versus host disease.